ProKidney Corp. Class A Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for PROK, updated each market day.
PROK AI Sentiment
AI sees no strong directional signal for ProKidney Corp. Class A Ordinary Shares stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ProKidney Corp. Class A Ordinary Shares
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Sector
Exchange
Market Cap
$269,691,519
Cap Tier
Employees
231
Headquarters
WINSTON-SALEM, NC
Listed Since
July 12, 2022
Website
PROK Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PROK Volatility
ProKidney Corp. Class A Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
